<DOC>
	<DOC>NCT00554606</DOC>
	<brief_summary>This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.</brief_summary>
	<brief_title>Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Patients (male and nonpregnant, nonlactating females) who completed the core CACZ885A2204, CACZ885A2206, or CACZ885A2207 study without serious or severe drugrelated adverse effects may enter the extension study upon signing informed consent Patients for whom continued treatment in the extension is not considered appropriate by the treating physician. Patients who were noncompliant or who demonstrated a major protocol violation in the core study. Patients who did not complete / discontinued from the core study. Patients with drug related serious adverse events or severe adverse events. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Anit-interleukin-1 beta</keyword>
	<keyword>ACZ885</keyword>
</DOC>